Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltoprazine for Levodopa-Induced Dyskinesia in Parkinson's Disease
2009-015928-28Phase 2Terminated
- Sponsor
- PsychoGenics
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Eltoprazine with Placebo (2 arms). Primary endpoints: Primary: Effective dose for dyskinesia suppression and Primary: Safety and tolerability. Started Aug 2010; status: terminated.
02
Drugs
eltoprazine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2009-015928-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015928-28.